Switzerland· 67521001
NUBEQA 300 mg, Filmtabletten
A darolutamide product containing darolutamidum, registered in Switzerland by Bayer (Schweiz) AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Darolutamide is registered in 15 of 19 countries.
Countries holding a registration under ATC L02BB06 (darolutamide), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Darolutamide · ATC L02BB06
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of darolutamide costs, country by country.
Normalised to the WHO defined daily dose (1.2 g), the median price runs from $0.86 in France to $129.97 in Switzerland — a ×151 gap.
- Switzerland: $129.97 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Darolutamide · price per daily dose (1.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$129.97
- FR France$0.86
The record
At a glance
Swissmedic (Switzerland)- Active substance
- darolutamidum
- Manufacturer
- Bayer (Schweiz) AG
- Country
- Switzerland (CH)
- ATC code
- L02BB06
- ATC class
- Darolutamide
- Defined daily dose
- 1.2 g, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680675210015Blist 112 StkCHF 3018
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
216 interactions on record for darolutamide.
Graded by severity as the source publishes them — 19 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Darolutamide · interactions on record
216 records
- 19 severe
- 141 moderate
- 56 minor
Most severe, free to view
- EluxadolineA07DA06severe
- BerotralstatB06AC06severe
- RosuvastatinC10AA07severe
- DexamethasoneH02AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Darolutamide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumNubeqa 300 mgBayer
- CzechiaNUBEQABayer AG, Leverkusen
- SpainNUBEQA 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULABayer Ag
- FinlandNubeqaBayer AG
- FranceNUBEQA 300 mg, comprimé pelliculéBAYER AG (ALLEMAGNE)
- IrelandNUBEQA 300 mg film-coated tabletsBayer AG
- IcelandNubeqaBayer AG*
- NetherlandsNubeqa 300 mg, filmomhulde tablettenBayer AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nubeqa
- Liechtenstein · Nubeqa
- Norway · Nubeqa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/12c799cd-4f88-4648-a669-8e5904f5b2ad GET /v1/drugs/12c799cd-4f88-4648-a669-8e5904f5b2ad?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "darolutamidum 300 mg",
"valid_from": "2025-11-01",
"limitations": "[{\"description\":\"<b>Für alle vergütungspflichtigen Indikationen gilt:</b><br>\\nFür NUBEQA wurde ein einheitlicher Abrechnungspreis festgelegt. Sind in spezifischen Fällen (z.B. Einzelfallvergütung) die wirtschaftlichen Preise in den jeweiligen Indikationen zu berücksichtigen, gibt die Zulassungsinhaberin auf Aufforderung der Krankenversicherung die Preise bekannt.<br>\\n<br>\\nNach Kostengutsprache des Krankenversicherers mit vorgängiger Konsultation des Vertrauensarztes.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21068.XX\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-06-01\",\"validTo\":\"2028-10-31\"},{\"description\":\"<b>mHSPC</b><br>\\nNUBEQA wird vergütet in Kombination mit Androgendeprivationstherapie (ADT) für die Behandlung von erwachsenen Patienten mit metastasiertem, hormonsensitivem Prostatakarzinom (mHSPC).<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"21068.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-11-01\",\"validTo\":\"2028-10-31\"},{\"description\":\"<b>mHSPC in Kombination mit Docetaxel</b><br>\\nNUBEQA, in Kombination mit Docetaxel und Androgendeprivationstherapie (ADT), wird vergütet für die Behandlung von erwachsenen Patienten mit metastasiertem, hochvolumigem/hochrisiko-hormonsensitivem Prostatakarzinom (mHSPC), für die eine Docetaxel-Therapie angezeigt ist (Eastern Cooperative Oncology Group (ECOG) performance-status score von 0 oder 1).<br>\\nDie Therapie wird maximal bis zur Progression der Erkrankung oder bis inakzeptable Toxizität auftritt, vergütet.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"21068.02\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-06-01\",\"validTo\":\"2028-10-31\"}]",
"galenic_form": "Filmtabl 300 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2023-04-01",
"self_retention_pct": 10
}See everything about darolutamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.